Anzeige
Erschienen in:
29.10.2018 | SHOULDER
Long-term outcome of arthroscopic remplissage in addition to the classic Bankart repair for the management of recurrent anterior shoulder instability with engaging Hill–Sachs lesions
Erschienen in: Knee Surgery, Sports Traumatology, Arthroscopy | Ausgabe 1/2019
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The evaluation of the long-term outcome of the arthroscopic remplissage performed in addition to the classic Bankart repair for the primary management of recurrent anterior shoulder instability with engaging Hill–Sachs lesion without inverted pear appearance of the glenoid during arthroscopy.
Methods
During a 6-year period, from 2007 to 2012, 65 patients whose average age was 30.1 ± 7.6 years were operated on in our department and satisfied the inclusion criteria of this study. They all had a positive apprehension sign preoperatively. Among them, 51 patients (82%) were available for long-term evaluation. The mean follow-up period was 8.1 ± 1.8 years (range 5.6–10.6).
Results
Three patients (5.6%) had suffered a new dislocation. The remaining patients (94.4%) were satisfied with the surgical result and returned to their previous daily activities, whereas 71% continued to participate in sports without restrictions. The ASES score increased from 72.5 (range 18–100) preoperatively to 100 (range 85–100) postoperatively (p < 0.01). The modified Rowe score increased from 40 (range 15–70) to 100 (range 70–100) (p < 0.001), and the Oxford Instability score from 29 (range 9–47) to 48 (range 36–48) (p < 0.001). No significant restriction in the shoulder range of motion was documented.
Conclusions
The combination of the arthroscopic remplissage with the classic Bankart repair was proven to be a safe and effective procedure for the treatment of “engaging” Hill–Sachs lesions without inverted pear appearance of the glenoid. This combination has long-term outcomes in terms of the recurrence rate and does not significantly influence the range of motion of the shoulder.
Level of evidence
Therapeutic Study—Case series with no comparison group, Level IV.